154 related articles for article (PubMed ID: 12939469)
1. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells.
Zhou C; Gehrig PA; Whang YE; Boggess JF
Mol Cancer Ther; 2003 Aug; 2(8):789-95. PubMed ID: 12939469
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest.
Bae-Jump VL; Zhou C; Gehrig PA; Whang YE; Boggess JF
Gynecol Oncol; 2006 Mar; 100(3):487-94. PubMed ID: 16249016
[TBL] [Abstract][Full Text] [Related]
3. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels.
Zhou C; Bae-Jump VL; Whang YE; Gehrig PA; Boggess JF
Gynecol Oncol; 2006 May; 101(2):305-10. PubMed ID: 16380156
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.
Bae-Jump VL; Zhou C; Boggess JF; Whang YE; Barroilhet L; Gehrig PA
Gynecol Oncol; 2010 Dec; 119(3):579-85. PubMed ID: 20863555
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis.
Shafer A; Zhou C; Gehrig PA; Boggess JF; Bae-Jump VL
Int J Cancer; 2010 Mar; 126(5):1144-54. PubMed ID: 19688827
[TBL] [Abstract][Full Text] [Related]
6. Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.
Sundin T; Peffley DM; Hentosh P
Mol Cell Biochem; 2013 Mar; 375(1-2):97-104. PubMed ID: 23283642
[TBL] [Abstract][Full Text] [Related]
7. IL-2 increases human telomerase reverse transcriptase activity transcriptionally and posttranslationally through phosphatidylinositol 3'-kinase/Akt, heat shock protein 90, and mammalian target of rapamycin in transformed NK cells.
Kawauchi K; Ihjima K; Yamada O
J Immunol; 2005 May; 174(9):5261-9. PubMed ID: 15843522
[TBL] [Abstract][Full Text] [Related]
8. Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.
Hanna RK; Zhou C; Malloy KM; Sun L; Zhong Y; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2012 May; 125(2):458-69. PubMed ID: 22252099
[TBL] [Abstract][Full Text] [Related]
9. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.
Cantrell LA; Zhou C; Mendivil A; Malloy KM; Gehrig PA; Bae-Jump VL
Gynecol Oncol; 2010 Jan; 116(1):92-8. PubMed ID: 19822355
[TBL] [Abstract][Full Text] [Related]
10. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
11. The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Mita MM; Mita A; Rowinsky EK
Cancer Biol Ther; 2003; 2(4 Suppl 1):S169-77. PubMed ID: 14508096
[TBL] [Abstract][Full Text] [Related]
12. [Effect of signal transduction inhibitors on human endometrial carcinoma cells with differential PTEN gene expression].
Xiao L; Yang YB; Shen HM; Xu CF; Wang XY; Li XM
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):681-5. PubMed ID: 20079181
[TBL] [Abstract][Full Text] [Related]
13. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
14. Determinants of rapamycin sensitivity in breast cancer cells.
Noh WC; Mondesire WH; Peng J; Jian W; Zhang H; Dong J; Mills GB; Hung MC; Meric-Bernstam F
Clin Cancer Res; 2004 Feb; 10(3):1013-23. PubMed ID: 14871980
[TBL] [Abstract][Full Text] [Related]
15. Effects of rapamycin on the mechanistic target of rapamycin (mTOR) pathway and telomerase in breast cancer cells.
Gopalakrishnan K; Venkatesan S; Low ESH; Hande MP
Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):103-113. PubMed ID: 30442335
[TBL] [Abstract][Full Text] [Related]
16. Mammalian target of rapamycin: a new molecular target for breast cancer.
Mita MM; Mita A; Rowinsky EK
Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
[TBL] [Abstract][Full Text] [Related]
17. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
[TBL] [Abstract][Full Text] [Related]
18. The expression of mammalian target of rapamycin in Ishikawa and HEC-1A cells.
Li X; Xiao L; Yang Y; Shen H; Zeng H; Wang Z
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):340-2. PubMed ID: 18563337
[TBL] [Abstract][Full Text] [Related]
19. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
Fong P; Meng LR
Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
[TBL] [Abstract][Full Text] [Related]
20. eIF4E-Overexpression imparts perillyl alcohol and rapamycin-mediated regulation of telomerase reverse transcriptase.
Sundin T; Peffley D; Hentosh P
Exp Cell Res; 2013 Aug; 319(13):2103-2112. PubMed ID: 23747720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
